tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising Future for Keros Therapeutics: Buy Rating Backed by Strategic Focus and Key Partnerships
PremiumRatingsPromising Future for Keros Therapeutics: Buy Rating Backed by Strategic Focus and Key Partnerships
2M ago
Keros Therapeutics Reports Strong Revenue Growth
Premium
Company Announcements
Keros Therapeutics Reports Strong Revenue Growth
2M ago
Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Financial Uncertainties
Premium
Ratings
Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Financial Uncertainties
2M ago
Keros Therapeutics announces share repurchase program
PremiumThe FlyKeros Therapeutics announces share repurchase program
3M ago
Keros Therapeutics Presents Promising Phase 1 Trial Data
Premium
Company Announcements
Keros Therapeutics Presents Promising Phase 1 Trial Data
4M ago
Keros Therapeutics presents additional clinical data from KER-065 program
Premium
The Fly
Keros Therapeutics presents additional clinical data from KER-065 program
4M ago
Keros Therapeutics’ treatment of Duchenne MD granted FDA orphan designation
PremiumThe FlyKeros Therapeutics’ treatment of Duchenne MD granted FDA orphan designation
5M ago
Keros Therapeutics Reports Strong Revenue Growth
Premium
Company Announcements
Keros Therapeutics Reports Strong Revenue Growth
5M ago
Strategic Focus on KER-065 and Leadership Changes Justify Buy Rating for Keros Therapeutics
Premium
Ratings
Strategic Focus on KER-065 and Leadership Changes Justify Buy Rating for Keros Therapeutics
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100